241 results on '"Al-Kuwari, Mohamed Ghaith"'
Search Results
2. COVID-19 testing, incidence, and positivity trends among school age children during the academic years 2020–2022 in the State of Qatar: special focus on using CDC indicators for community transmission to evaluate school attendance policies and public health response
3. Prevalence of hepatitis B and C viruses among migrant workers in Qatar
4. Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar
5. Sickness absenteeism among primary health care workers in Qatar before and during the COVID-19 pandemic
6. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study
7. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
8. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
9. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
10. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
11. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
12. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
13. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
14. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
15. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
16. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
17. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
18. BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar.
19. Assessing the impact of annual health screenings in identifying noncommunicable disease risk factors within Qatar’s primary health care corporation Qatari registered population
20. Post-COVID-19 syndrome, who at risk and why: an insight from Qatar 2022
21. Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study
22. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
23. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient
24. Epidemiology of SARS-CoV2 in Qatar’s primary care population aged 10 years and above
25. COVID-19 infection across workplace settings in Qatar: a comparison of COVID-19 positivity rates of screened workers from March 1st until July 31st, 2020
26. Tobacco control in Qatar from 2002 to 2022: 20 years of progress and challenges
27. SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
28. Epidemiology of scorpion sting and snakebite cases in Qatar 2018–2022: A primary care-based study
29. History of primary-series and booster vaccination and protection against Omicron reinfection
30. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
31. Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation.
32. Primary health care capacity assessment in Qatar: the primary health care progression model as an assessment method
33. A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar
34. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: An observational study
35. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections
36. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
37. Short- and longer-term all-cause mortality among SARS-CoV-2- infected persons and the pull-forward phenomenon in Qatar
38. Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infection
39. 1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections.
40. COVID-19 primary series and booster vaccination and potential for immune imprinting
41. Duration of immune protection of SARS-CoV-2 natural infection against reinfection
42. Understanding the epidemiological characteristics of the primary healthcare corporation-based COVID-19 swabbed persons in Qatar, 2020
43. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
44. Immune protection against SARS-CoV-2 re-reinfection and immune imprinting
45. Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar
46. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants
47. Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
48. Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
49. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
50. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.